Real-World Translation For a 250-pound person: *Assuming 5'10" height Difference: Retatrutide loses 21 more pounds than CagriSema
The model predicted rapid weight regain immediately after cessation, followed by a slowdown and a gradual approach toward a plateau in the months thereafter
People living with type-2 diabetes and/or obesity have the greatest opportunity for prescription savings on GLP-1s, compared to insulin, medical devices (e.g., blood glucose monitors), and other medications at CVS
Additionally, the growing popularity of GLP-1 receptor agonists as treatments for obesity presents immense opportunities for biosimilar players
Nasseri focuses on preventative wellness, helping his clients stay ahead of health concerns with a holistic, individualized approach
Artif Cells Nanomed Biotechnol 46(6):12361247